OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SVA, BIIB, LLY, BSX, ISRG, and represent 22.56% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: LLY (+$105M), BIIB (+$70M), ELV (+$67M), SRRK (+$42M), ARGX (+$20M), SRPT (+$16M), ALNY (+$15M), RCM (+$14M), PFE (+$14M), NBIX (+$14M).
- Started 14 new stock positions in GERN, PFE, FATE, ALNY, FOLD, ILMN, RCUS, AGIO, ELV, KRYS. Ambrx Biopharma, CLDX, TXG, VIR.
- Reduced shares in these 10 stocks: HUM (-$107M), MRTX (-$90M), BAX (-$85M), CI (-$66M), , CRNX (-$44M), MDGL (-$37M), IRON (-$33M), Horizon Therapeutics (-$31M), ALPN (-$30M).
- Sold out of its positions in ABBV, AKRO, ALT, ARQT, AZN, BAX, BCAB, CI, CUTR, EPIX.
- Orbimed Advisors was a net seller of stock by $-410M.
- Orbimed Advisors has $5.0B in assets under management (AUM), dropping by 5.93%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Orbimed Advisors
Orbimed Advisors holds 110 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Sinovac Biotech SHS (SVA) | 6.8 | $340M | 2.7M | 125.06 |
|
|
Biogen Idec (BIIB) | 4.3 | $214M | +48% | 828k | 258.77 |
|
Eli Lilly & Co. (LLY) | 4.3 | $213M | +96% | 365k | 582.92 |
|
Boston Scientific Corporation (BSX) | 3.8 | $191M | 3.3M | 57.81 |
|
|
Intuitive Surgical Com New (ISRG) | 3.4 | $168M | 499k | 337.36 |
|
|
Edgewise Therapeutics (EWTX) | 3.2 | $159M | 15M | 10.94 |
|
|
BioMarin Pharmaceutical (BMRN) | 3.0 | $152M | -2% | 1.6M | 96.42 |
|
Rayzebio (RYZB) | 2.9 | $147M | -9% | 2.4M | 62.17 |
|
Enliven Therapeutics (ELVN) | 2.5 | $125M | 9.0M | 13.84 |
|
|
Springworks Therapeutics (SWTX) | 2.4 | $118M | -18% | 3.2M | 36.50 |
|
Merck & Co (MRK) | 2.3 | $115M | 1.1M | 109.02 |
|
|
Ionis Pharmaceuticals (IONS) | 2.1 | $105M | -4% | 2.1M | 50.59 |
|
Disc Medicine (IRON) | 2.0 | $98M | -24% | 1.7M | 57.76 |
|
Gracell Biotechnologies Sponsored Ads (GRCL) | 1.9 | $94M | 9.3M | 10.04 |
|
|
Tenet Healthcare Corp Com New (THC) | 1.9 | $93M | 1.2M | 75.57 |
|
|
Evolent Health Cl A (EVH) | 1.8 | $91M | -5% | 2.7M | 33.03 |
|
United Therapeutics Corporation (UTHR) | 1.7 | $85M | -3% | 386k | 219.89 |
|
Xtant Med Hldgs Com New (XTNT) | 1.7 | $83M | 73M | 1.13 |
|
|
Stryker Corporation (SYK) | 1.6 | $81M | 269k | 299.46 |
|
|
Scholar Rock Hldg Corp (SRRK) | 1.6 | $80M | +108% | 4.2M | 18.80 |
|
Thermo Fisher Scientific (TMO) | 1.5 | $76M | 144k | 530.79 |
|
|
Verona Pharma Sponsored Ads (VRNA) | 1.5 | $75M | 3.8M | 19.88 |
|
|
Vaxcyte (PCVX) | 1.4 | $72M | +14% | 1.2M | 62.80 |
|
Theseus Pharmaceuticals (THRX) | 1.4 | $72M | 18M | 4.05 |
|
|
Vertex Pharmaceuticals Incorporated (VRTX) | 1.4 | $71M | +5% | 175k | 406.89 |
|
Neurocrine Biosciences (NBIX) | 1.4 | $68M | +24% | 519k | 131.76 |
|
Sarepta Therapeutics (SRPT) | 1.3 | $67M | +31% | 698k | 96.43 |
|
Anthem (ELV) | 1.3 | $67M | NEW | 142k | 471.56 |
|
Third Harmonic Bio (THRD) | 1.3 | $63M | 5.8M | 10.97 |
|
|
Natera (NTRA) | 1.2 | $60M | +3% | 955k | 62.64 |
|
Crinetics Pharmaceuticals In (CRNX) | 1.2 | $59M | -42% | 1.7M | 35.58 |
|
Apellis Pharmaceuticals (APLS) | 1.1 | $55M | -31% | 922k | 59.86 |
|
R1 RCM (RCM) | 1.0 | $51M | +39% | 4.8M | 10.57 |
|
Silverback Therapeutics (SPRY) | 1.0 | $51M | 9.2M | 5.48 |
|
|
Keros Therapeutics (KROS) | 1.0 | $50M | -16% | 1.3M | 39.76 |
|
Humana (HUM) | 1.0 | $50M | -67% | 110k | 457.81 |
|
Terns Pharmaceuticals (TERN) | 1.0 | $49M | 7.6M | 6.49 |
|
|
Alpine Immune Sciences (ALPN) | 1.0 | $48M | -37% | 2.5M | 19.06 |
|
Si-bone (SIBN) | 1.0 | $48M | 2.3M | 20.99 |
|
|
Prelude Therapeutics (PRLD) | 0.9 | $47M | 11M | 4.27 |
|
|
Alx Oncology Hldgs (ALXO) | 0.9 | $46M | +7% | 3.1M | 14.89 |
|
Neuropace (NPCE) | 0.8 | $41M | 4.0M | 10.31 |
|
|
Iovance Biotherapeutics (IOVA) | 0.8 | $38M | 4.7M | 8.13 |
|
|
Syndax Pharmaceuticals (SNDX) | 0.8 | $38M | +36% | 1.7M | 21.61 |
|
Icon SHS (ICLR) | 0.7 | $37M | 132k | 283.07 |
|
|
UnitedHealth (UNH) | 0.7 | $37M | 70k | 526.47 |
|
|
Amgen (AMGN) | 0.7 | $37M | 127k | 288.02 |
|
|
Apogee Therapeutics (APGE) | 0.7 | $36M | -10% | 1.3M | 27.94 |
|
Janux Therapeutics (JANX) | 0.7 | $36M | 3.3M | 10.73 |
|
|
Compass Therapeutics (CMPX) | 0.7 | $35M | 22M | 1.56 |
|
|
Scpharmaceuticals (SCPH) | 0.7 | $35M | 5.6M | 6.27 |
|
|
Argenx Se Sponsored Adr (ARGX) | 0.6 | $32M | +159% | 85k | 380.43 |
|
Fusion Pharmaceuticals (FUSN) | 0.6 | $30M | 3.1M | 9.61 |
|
|
Acelyrin (SLRN) | 0.6 | $30M | -24% | 4.0M | 7.46 |
|
Neumora Therapeutics (NMRA) | 0.5 | $26M | 1.5M | 17.05 |
|
|
Xenon Pharmaceuticals (XENE) | 0.5 | $25M | -42% | 550k | 46.06 |
|
Rhythm Pharmaceuticals (RYTM) | 0.5 | $25M | -8% | 537k | 45.97 |
|
Repare Therapeutics Ord (RPTX) | 0.5 | $24M | 3.3M | 7.30 |
|
|
Abcellera Biologics (ABCL) | 0.5 | $24M | 4.2M | 5.71 |
|
|
Ikena Oncology Nonvoting | 0.5 | $24M | 12M | 1.97 |
|
|
Vera Therapeutics Cl A (VERA) | 0.5 | $23M | 1.5M | 15.38 |
|
|
Pmv Pharmaceuticals (PMVP) | 0.4 | $20M | 6.5M | 3.10 |
|
|
Kinnate Biopharma (KNTE) | 0.4 | $19M | 8.0M | 2.37 |
|
|
Tela Bio (TELA) | 0.4 | $19M | 2.8M | 6.62 |
|
|
Aerovate Therapeutics (AVTE) | 0.3 | $17M | 757k | 22.63 |
|
|
Adagio Therapeutics (IVVD) | 0.3 | $16M | -21% | 4.1M | 3.94 |
|
Immatics SHS (IMTX) | 0.3 | $16M | +31% | 1.5M | 10.53 |
|
Adicet Bio (ACET) | 0.3 | $16M | 8.3M | 1.89 |
|
|
Alnylam Pharmaceuticals (ALNY) | 0.3 | $15M | NEW | 79k | 191.41 |
|
Pfizer Call Option (PFE) | 0.3 | $14M | NEW | 500k | 28.79 |
|
Krystal Biotech (KRYS) | 0.3 | $13M | NEW | 104k | 124.06 |
|
Verastem Com New (VSTM) | 0.2 | $12M | 1.5M | 8.14 |
|
|
Corvus Pharmaceuticals (CRVS) | 0.2 | $12M | 6.9M | 1.76 |
|
|
Regeneron Pharmaceuticals (REGN) | 0.2 | $12M | 14k | 878.29 |
|
|
Amicus Therapeutics (FOLD) | 0.2 | $11M | NEW | 806k | 14.19 |
|
Passage Bio (PASG) | 0.2 | $10M | 10M | 1.01 |
|
|
Heron Therapeutics (HRTX) | 0.2 | $10M | +638% | 5.9M | 1.70 |
|
Arrowhead Pharmaceuticals (ARWR) | 0.2 | $9.8M | -26% | 320k | 30.60 |
|
Uniqure Nv SHS (QURE) | 0.2 | $9.1M | -34% | 1.3M | 6.77 |
|
Dex (DXCM) | 0.2 | $9.1M | +46% | 73k | 124.09 |
|
Apollomics Cl A Shs (APLM) | 0.2 | $8.3M | -52% | 8.6M | 0.96 |
|
Gilead Sciences (GILD) | 0.2 | $8.1M | 100k | 81.01 |
|
|
Morphic Hldg (MORF) | 0.2 | $7.9M | +31% | 273k | 28.88 |
|
Turnstone Biologics Corp (TSBX) | 0.2 | $7.9M | 3.1M | 2.54 |
|
|
Rapt Therapeutics (RAPT) | 0.1 | $7.0M | -77% | 281k | 24.85 |
|
Ikena Oncology (IKNA) | 0.1 | $7.0M | +11% | 3.5M | 1.97 |
|
Inspiremd (NSPR) | 0.1 | $6.0M | +14% | 2.1M | 2.81 |
|
X4 Pharmaceuticals (XFOR) | 0.1 | $6.0M | 7.1M | 0.84 |
|
|
Cullinan Oncology (CGEM) | 0.1 | $5.6M | 545k | 10.19 |
|
|
Oric Pharmaceuticals (ORIC) | 0.1 | $4.8M | -41% | 523k | 9.20 |
|
Illumina (ILMN) | 0.1 | $4.2M | NEW | 30k | 139.24 |
|
Ambrx Biopharma | 0.1 | $4.2M | NEW | 296k | 14.24 |
|
Nextcure (NXTC) | 0.1 | $3.1M | 2.7M | 1.14 |
|
|
Celldex Therapeutics Com New (CLDX) | 0.0 | $2.3M | NEW | 59k | 39.66 |
|
Arcus Biosciences Incorporated (RCUS) | 0.0 | $2.2M | NEW | 117k | 19.10 |
|
10x Genomics Cl A Com (TXG) | 0.0 | $2.2M | NEW | 40k | 55.96 |
|
Fate Therapeutics (FATE) | 0.0 | $2.0M | NEW | 528k | 3.74 |
|
Kezar Life Sciences (KZR) | 0.0 | $1.8M | -64% | 1.9M | 0.95 |
|
Bolt Biotherapeutics (BOLT) | 0.0 | $1.7M | 1.5M | 1.12 |
|
|
Ys Biopharma Ordinary Shares (YS) | 0.0 | $1.7M | -28% | 3.2M | 0.51 |
|
Vigil Neuroscience (VIGL) | 0.0 | $1.5M | 449k | 3.38 |
|
|
Chardan Healthcare Acqu- Ord (PHGE) | 0.0 | $1.3M | 4.5M | 0.28 |
|
|
Chemomab Therapeutics Sponsored Ads (CMMB) | 0.0 | $1.1M | 2.2M | 0.51 |
|
|
Geron Corporation (GERN) | 0.0 | $1.0M | NEW | 485k | 2.11 |
|
Vir Biotechnology (VIR) | 0.0 | $1.0M | NEW | 101k | 10.06 |
|
Agios Pharmaceuticals (AGIO) | 0.0 | $1.0M | NEW | 45k | 22.27 |
|
Calcimedica Com New (CALC) | 0.0 | $851k | 297k | 2.86 |
|
|
Elevation Oncology (ELEV) | 0.0 | $806k | 1.5M | 0.54 |
|
|
Acutus Medical (AFIB) | 0.0 | $535k | 2.6M | 0.20 |
|
|
Singular Genomics Systems In (OMIC) | 0.0 | $249k | 541k | 0.46 |
|
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2023 Q4 filed Feb. 14, 2024
- Orbimed Advisors 2023 Q3 filed Nov. 14, 2023
- Orbimed Advisors 2023 Q2 filed Aug. 14, 2023
- Orbimed Advisors 2023 Q1 filed May 15, 2023
- Orbimed Advisors 2022 Q4 filed Feb. 14, 2023
- Orbimed Advisors 2022 Q3 filed Nov. 14, 2022
- Orbimed Advisors 2022 Q2 filed Aug. 15, 2022
- Orbimed Advisors 2022 Q1 filed May 16, 2022
- Orbimed Advisors 2021 Q4 filed Feb. 14, 2022
- Orbimed Advisors 2021 Q3 filed Nov. 15, 2021
- Orbimed Advisors 2021 Q2 filed Aug. 16, 2021
- Orbimed Advisors 2021 Q1 filed May 17, 2021
- Orbimed Advisors 2020 Q4 filed Feb. 16, 2021
- Orbimed Advisors 2020 Q3 filed Nov. 16, 2020
- Orbimed Advisors 2020 Q2 filed Aug. 14, 2020
- Orbimed Advisors 2020 Q1 filed May 15, 2020